Hostname: page-component-cd9895bd7-dzt6s Total loading time: 0 Render date: 2024-12-28T04:45:27.228Z Has data issue: false hasContentIssue false
  • English
  • Français

Heterogeneity in the response of pigs and mice to specific CpG oligodeoxynucleotides

Published online by Cambridge University Press:  12 February 2007

Li Guang-Fu ,
Zhu Hong-Fei ,
Shao Guo-Qing ,
Zhu Jian-Zhong ,
Ma Yan-Qing  and
Zhang Zhao-Song
Li Guang-Fu*
Affiliation:
Institute for Molecular Biology of Medicine, Nanjing Medical University, Nanjing 210029, China
Zhu Hong-Fei
Affiliation:
Institute for Bioengineering, Nanjing Agricultural University, Nanjing 210095, China
Shao Guo-Qing
Affiliation:
Institute of Animal Science and Veterinary Medicine, Jiangsu Academy of Agricultural Sciences, Nanjing 210014, China
Zhu Jian-Zhong
Affiliation:
Institute for Molecular Biology of Medicine, Nanjing Medical University, Nanjing 210029, China
Ma Yan-Qing
Affiliation:
Institute for Molecular Biology of Medicine, Nanjing Medical University, Nanjing 210029, China
Zhang Zhao-Song
Affiliation:
Institute for Molecular Biology of Medicine, Nanjing Medical University, Nanjing 210029, China
*
*Corresponding author: Email: guangfu@njmu.edu.cn
Get access Rights & Permissions [Opens in a new window]

Abstract

Differences in immunostimulation activity of CpG oligodeoxynucleotides (ODNs) between pigs and mice were studied. In accordance with current research data, three kinds of CpG ODN – 2006, D19 and 1826, which were identified as optimally active in humans, pigs and mice, respectively – and control ODN D48, a non CpG-containing ODN, were selected and synthesized. Results indicated that CpG ODN D19 strongly stimulated the proliferation of porcine peripheral blood mononuclear cells (PBMCs), and the amount of γ-interferon in the supernatant of activated cells increased, exceeding that of all other ODNs tested, while mouse splenocytes did not respond. CpG ODN 1826 strongly stimulated the proliferation of mouse splenocytes, but porcine PBMCs remained unresponsive. CpG ODN 2006 effectively stimulated proliferation of both porcine PBMCs and mouse splenocytes. Therefore some specific CpG ODNs, D19 and 1826, selectively stimulated animal species, while CpG ODN 2006 possessed a common stimulation effect. In addition, CpG ODN D19 predominantly induced the response of type 1 T-helper cells in vivo.

Keywords

CpG oligodeoxynucleotideheterogeneityγ-interferonCpG motif
Type
Research Article
Information
Chinese Journal of Agricultural Biotechnology , Volume 1 , Issue 2 , August 2004 , pp. 109 - 114
Copyright
Copyright © China Agricultural University and Cambridge University Press 2004

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bauer, M, Heeg, K and Wagner, H et al. . (1999) DNA activates human immune cells through a CpG sequence-dependent manner. Immunology 97: 699–705.Google Scholar
Elias, F, Flo, J and Lopez, RA (2003) Strong cytosine–guanosine-independent immunostimulation in humans and other primates by synthetic oligodeoxynucleotides with PyNTTTTGT motifs. Journal of Immunology 171: 3697–3704.Google Scholar
Elkins, KL, Rhinehart-Jones, TR and Stibitz, S et al. . (1999) Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria. Journal of Immunology 162: 2291–2298.CrossRefGoogle ScholarPubMed
Gramzinski, RA, Doolan, DL and Sedegah, M (2001) Interleukin-12-α and gamma interferon-dependent protection against malaria conferred by CpG oligodeoxynucleotide in mice. Infection and Immunity 69: 1643–1649.Google Scholar
Hartmann, G, Weeratna, RD and Ballas, ZK et al. . (2000) Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. Journal of Immunology 164: 1617–1624.CrossRefGoogle ScholarPubMed
Jakob, T, Walker, PS and Krieg, AM (1999) Bacterial DNA and CpG-containing oligodeoxynucleotides activate cutaneous dendritic cells and induce IL-12 production: implications for the augmentation of Th1 responses. International Archives of Allergy and Immunology 118: 457–461.Google Scholar
Kline, JN (2000) Effect of CpG DNA on Th1/Th2 balance in asthma. Current Topics in Microbiology and Immunology 247: 211–225.Google Scholar
Krieg, AM, Yi, AK and Matson, S et al. . (1995) CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374: 546–549.Google Scholar
Lefeber, DJ, Benaissa-Trouw, B and Vliegenthart, JF (2003) Th1-directing adjuvants increase the immunogenicity of oligosaccharide–protein conjugate vaccines related to Streptococcus pneumoniae type 3. Infection and Immunity 71: 6915–6920.Google Scholar
Rankin, R, Pontarollo, R, Ioannou, X and Krieg, AM (2001) CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved. Antisense & Nucleic Acid Drug Development 11: 333–340.CrossRefGoogle ScholarPubMed
Rothenfusser, S, Hornung, V and Krug, A (2001) Distinct CpG oligonucleotide sequences activate human gamma delta T cells via interferon-alpha/-beta. European Journal of Immunology 31: 3525–3534.Google Scholar
Søren, K, Danila, V and Dennis, MK (2001) Response of porcine peripheral blood mononuclear cells to CpG-containing oligodeoxynucleotides. Veterinary Microbiology 78: 353–362.Google Scholar
Tokunaga, T, Yamamoto, H and Shimada, S et al. . (1984) Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. Journal of the National Cancer Institute 72: 955–962.Google Scholar
Van der Stede, Y, Verdonck, F and Vancaeneghem, S (2002) CpG-oligodinucleotides as an effective adjuvant in pigs for intramuscular immunizations. Veterinary Immunology and Immunopathology 86: 31–41.Google Scholar
Verthelyi, D and Klinman, DM (2003) Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primates. Clinical Immunology 109: 64–71.Google Scholar
Weiner, GJ (2000) CpG DNA in cancer immunotherapy. Current Topics in Microbiology and Immunology 247: 157–170.Google Scholar